Skip to main content
Premium Trial:

Request an Annual Quote

Frost & Sullivan Forecast Growth, Changes in Reagent Market

NEW YORK, Feb. 20-Revenues for biomedical research reagents in the United States climbed to $981 million last year and may be worth more than $2 billion by 2007, according to a new report from Frost & Sullivan.


The report, "U.S. Research Biochemical Markets," tracks the growth of demand for biochemicals like antibodies and enzymes that are used in immunochemistry, cell culture work and genomic research.


The market is strong, but the report warns that it is also changing rapidly. Patent expirations are transforming the business. As patents expire, reagents become more widely available as products. Competition intensifies, prices drop, and profit margins can dwindle.


As a result, biochemical makers will face pressure unless they find ways to protect their patents and intellectual property.


One strategy: to use old products in new combination technologies.


Another strategy: strengthening brand image. "Market leaders in research biochemicals industry have very well-respected, long standing brand names," said Frost & Sullivan analyst Brad Peters in a statement released by the company.


The consulting company also recognized six companies in the biochemical industry with "Marketing Engineering Awards": Applied Biosystems, Invitrogen, New England Biolabs, NuGEN Technologies, Promega, and Roche Applied Science.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more